de Moraes F, de Castro Ribeiro C, Pessoa F, Chaves J, de Souza A, Di Felipe Avila Alcantara D
Breast Cancer Res. 2025; 27(1):39.
PMID: 40089780
DOI: 10.1186/s13058-025-01989-9.
Garrett J, Tendler S, Feroz W, Kilroy M, Yu H
Nat Rev Clin Oncol. 2025; .
PMID: 40087402
DOI: 10.1038/s41571-025-01008-y.
Zhang Y, Shang H, Zhang J, Jiang Y, Li J, Xiong H
Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006075
PMC: 11859690.
DOI: 10.3390/ph18020262.
Pan Y, Xiang Q, Deng K, Anwar M, Wang L, Wang Y
Protein Sci. 2025; 34(3):e70051.
PMID: 39969096
PMC: 11837023.
DOI: 10.1002/pro.70051.
Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M
Adv Exp Med Biol. 2025; 1464():495-525.
PMID: 39821040
DOI: 10.1007/978-3-031-70875-6_24.
Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.
Bai X, Xu L, Wang Z, Zhuang X, Ning J, Sun Y
Proc Natl Acad Sci U S A. 2025; 122(1):e2413686122.
PMID: 39793038
PMC: 11725927.
DOI: 10.1073/pnas.2413686122.
Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.
Li F, Li J, Ji C, Wu S, Zhang S, Wang T
Oncologist. 2025; 30(1).
PMID: 39786451
PMC: 11783281.
DOI: 10.1093/oncolo/oyae144.
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.
Mihaylova R, Momekova D, Elincheva V, Momekov G
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770542
PMC: 11677665.
DOI: 10.3390/ph17121701.
Guiding Competitive Binding Assays Using Protein-Protein Interaction Prediction: The HER2-Affitin Use Case.
Ranaudo A, Cosentino U, Greco C, Moro G, Maiocchi A, Moroni E
ACS Omega. 2024; 9(50):49522-49529.
PMID: 39713642
PMC: 11656212.
DOI: 10.1021/acsomega.4c07317.
Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab.
Yamaguchi R, Uchiyama M, Miyazaki M, Hayashi T, Oyabu K, Nakano T
Cancer Diagn Progn. 2024; 4(6):722-728.
PMID: 39502602
PMC: 11534052.
DOI: 10.21873/cdp.10387.
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo.
Wang Z, Liu Y, Xu Y, Lu L, Zhu Z, Lv B
MAbs. 2024; 16(1):2412881.
PMID: 39381966
PMC: 11469434.
DOI: 10.1080/19420862.2024.2412881.
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
Waks A, Martinez-Saez O, Tarantino P, Braso-Maristany F, Pascual T, Cortes J
Nat Rev Clin Oncol. 2024; 21(11):818-832.
PMID: 39271787
DOI: 10.1038/s41571-024-00939-2.
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies.
Mo C, Sterpi M, Jeon H, Bteich F
Cancers (Basel). 2024; 16(16).
PMID: 39199625
PMC: 11352490.
DOI: 10.3390/cancers16162854.
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth.
Hu L, Zhang S, Sienkiewicz J, Zhou H, Berahovich R, Sun J
Vaccines (Basel). 2024; 12(7).
PMID: 39066446
PMC: 11281407.
DOI: 10.3390/vaccines12070808.
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded,....
Zuo W, Wang Z, Qian J, Ma X, Niu Z, Ou J
Br J Cancer. 2024; 131(4):668-675.
PMID: 38906970
PMC: 11333611.
DOI: 10.1038/s41416-024-02751-2.
Epitope binning for multiple antibodies simultaneously using mammalian cell display and DNA sequencing.
Lin N, Miyamoto K, Ogawara T, Sakurai S, Kizaka-Kondoh S, Kadonosono T
Commun Biol. 2024; 7(1):652.
PMID: 38806676
PMC: 11133372.
DOI: 10.1038/s42003-024-06363-7.
KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li C, Wang W, Leung C, Yang G, Chen J
Mol Cancer. 2024; 23(1):109.
PMID: 38769556
PMC: 11103982.
DOI: 10.1186/s12943-024-02011-0.
Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study.
He M, Zhao W, Wang P, Li W, Chen H, Yuan Z
Front Med (Lausanne). 2024; 11:1383279.
PMID: 38741766
PMC: 11089149.
DOI: 10.3389/fmed.2024.1383279.
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
Liefaard M, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S
NPJ Breast Cancer. 2024; 10(1):29.
PMID: 38637568
PMC: 11026378.
DOI: 10.1038/s41523-024-00636-4.
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.
Bonomi M, Spada D, Baiocchi G, Celotti A, Brighenti M, Grizzi G
Int J Mol Sci. 2024; 25(7).
PMID: 38612688
PMC: 11011631.
DOI: 10.3390/ijms25073876.